Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer

Jason D. Wright, Dana Viviano, Matthew A. Powell, Randall K. Gibb, David G. Mutch, Perry W. Grigsby, Janet S. Rader

Research output: Contribution to journalArticlepeer-review

99 Scopus citations


Objective.: To report the utility of the monoclonal, anti-vascular endothelial growth factor antibody bevacizumab in combination with cytotoxic chemotherapy for women with recurrent cervical cancer. Methods.: A retrospective analysis of women with recurrent cervical cancer treated with bevacizumab combination therapy was performed. Results.: Six patients were identified. The patients had a median of 3 prior regimens. All of the patients had multisite, metastatic disease. The combination regimen included IV 5-fluorouracil in 5 (83%) patients and capecitabine in one (17%) subject. Treatment was well tolerated. Grade 4 toxicity occurred in one patient who developed neutropenic sepsis. Clinical benefit (CR, PR, or SD) was noted in 67% of the subjects. This included 1 (17%) complete response, 1 (17%) partial response and two (33%) patients with stable disease. The median time to progression for the four women who demonstrated clinical benefit was 4.3 months. Conclusions.: Combination bevacizumab is well tolerated and displayed encouraging anti-tumor activity in heavily pretreated recurrent cervical cancer.

Original languageEnglish
Pages (from-to)489-493
Number of pages5
JournalGynecologic oncology
Issue number2
StatePublished - Nov 2006


  • Angiogenesis
  • Bevacizumab
  • Biologic therapy
  • Cervical cancer


Dive into the research topics of 'Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer'. Together they form a unique fingerprint.

Cite this